Therapeutic Solutions International, Inc. Announces Definitive Agreement With S4S (UK) Limited

Therapeutic Solutions International, Inc. Announces Definitive Agreement With 
S4S (UK) Limited 
TSI Obtains Exclusive Distribution Rights to FDA Cleared and Patented
Sleep Appliance Hardware 
OCEANSIDE, CA -- (Marketwired) -- 06/18/13 --  Therapeutic Solutions
International, Inc. (OTCQB: TSOI) announced today the signing of a
Distribution Agreement with S4S (UK) Limited for exclusive
distribution rights in the United States to market the U.S. patented
and FDA cleared titratable sleep appliance hardware sold under the
trademark "Sleepwell(TM)". 
"Today was a major achievement and milestone for S4S and our ever
popular Sleepwell(TM) appliance, which has been so successful in
Europe," stated Matt Everatt, Technical Director of S4S (UK) Limited.
"Our signing of this agreement with TSI to exclusively distribute the
Sleepwell appliance hardware will give US dentists a new product that
can help individuals suffering from snoring and sleep apnea."  
Dr. Barry Glassman, VP of Education and Training of Therapeutic
Solutions International, stated, "This proven technology is a very
attractive choice for both the dentist providing oral appliance
therapy, and for the patient seeking an alternative treatment for
sleep disturbed breathing, compared to the traditional therapies
including surgery and CPAP." 
"We at TSI are excited about bringing this quality yet cost effective
appliance choice to the United States," said CEO Tim Dixon of
Therapeutic Solutions International, who added, "According to the US
Department of Health and Human Services the prevalence of sleep apnea
in the US population is similar to asthma (20 million patients) and
diabetes (23.6 million patients). We look forward to working with
dentists and dental laboratories in bringing this product to the
patient."  
Sleepwell(TM) components are used to manufacture the appliance in a
dental laboratory using a bilaminate material customized to the
patient's teeth with a special soft inner lining for maximum comfort
and retention. The appliance also incorporates a specially designed
component made from medical grade 316 Stainless Steel, which ensures
that the lower jaw is held in a forward position while permitting the
wearer side-to-side movement during sleep.  
Therapeutic Solutions International is also 
a global manufacturer of
the chairside anterior midpoint stop appliance (AMPSA) devices
marketed internationally under the trade names Migran-X(R) and AMPSA
CS(R), which have helped countless patients prevent debilitating
migraine and tension headache pain, bruxism, clenching, grinding, and
TMJ disorders. The Migran-X(R) and AMPSA CS(R) devices are the most
effective non-drug US FDA cleared dental method of migraine
prevention on the market today.  
About Therapeutic Solutions International, Inc. 
The Company's corporate website is www.therapeuticsolutionsint.com.
Non-US dentists and physicians can order our AMPSA products at
www.ordertsoi.com. For the Sleepwell(TM) product, clinical data can
be viewed at www.sleepwelldevice.com. 
Safe Harbor Statement
 This release contains forward-looking
statements that are based upon current expectations or beliefs, as
well as a number of assumptions about future events. Although we
believe that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are
reasonable, we can give no assurance that such expectations and
assumptions will prove to have been correct. Forward-looking
statements are generally identifiable by the use of words like "may,"
"will," "should," "could," "expect," "anticipate," "estimate,"
"believe," "intend," or "project" or the negative of these words or
other variations on these words or comparable terminology. The reader
is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous risk factors
as set forth in our SEC filings. To the extent that statements in
this press release are not strictly historical, including statements
as to product launch timing, revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals,
future collaboration agreements, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made. Readers
are advised to review our filings with the Securities and Exchange
Commission that can be accessed over the Internet at the SEC's
website located at www.sec.gov. 
For more information please contact:
Therapeutic Solutions International, Inc.
ir@tsoimail.com